Splash
Verona Pharma

Breath of Innovation™

Verona Pharma is developing life enhancing treatments for respiratory diseases.
Splash
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company). Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties. Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China.

We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.

We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.

COPD
The unmet need

COPD

Cystic Fibrosis

Asthma

Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.

The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the World Health Organization.

Find out more

Latest Film

Verona Pharma's novel COPD candidate "has the potential to significantly benefit patients," believes CMO Dr Kathleen Rickard

Play

Splash

© Verona Pharma plc 2021. All rights reserved